CHP
BPMC

Cable Hill Partners’s Blueprint Medicines BPMC Stock Holding History

Cable Hill Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-52
Closed -$4K – 194
2019
Q1 		$4K Hold
52
– – ﹤0.01% 643
2018
Q4 		$3K Hold
52
– – ﹤0.01% 639
2018
Q3 		$4K Buy
+52
New +$3.61K ﹤0.01% 604

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cable Hill Partners's BPMC Position: Q2 2019 in Review

Cable Hill Partners sold out of Blueprint Medicines (BPMC) in Q2 2019, closing a stake of 52 shares — an estimated $4K sold.

Cable Hill Partners first reported a position in BPMC in Q3 2018 and held it in 3 quarters. The position peaked at $4K in Q1 2019. 220 funds tracked by Wall St. Rank hold BPMC as of Q2 2019.

  • Cable Hill Partners reported no remaining Blueprint Medicines position as of Q2 2019 after selling out during the quarter.
  • Cable Hill Partners sold 52 Blueprint Medicines shares in Q2 2019, an estimated $4K.
  • Cable Hill Partners first reported a position in Blueprint Medicines in Q3 2018 and held it in 3 quarters.
  • Cable Hill Partners's Blueprint Medicines position peaked at $4K in Q1 2019.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.